Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Carmela Gnerre, Jérôme Segrestaa, Swen Seeland, Päivi Äänismaa, Thomas Pfeifer, Stephane Delahaye, Ruben de Kanter, Tomohiko Ichikawa, Tetsuhiro Yamada & Alexander Treiber. (2018) The metabolism and drug–drug interaction potential of the selective prostacyclin receptor agonist selexipag. Xenobiotica 48:7, pages 704-719.
Read now
Read now
Articles from other publishers (12)
Rajesh Kumar, Charanjit Kaur, Kawalpreet Kaur, Navneet Khurana & Gurvinder Singh. (2023) Prodrugs: Harnessing chemical modifications for improved therapeutics. Journal of Drug Delivery Science and Technology 90, pages 105103.
Crossref
Crossref
Francesco Amati, Gabriele Bongiovanni, Antonio Tonutti, Francesca Motta, Anna Stainer, Giuseppe Mangiameli, Stefano Aliberti, Carlo Selmi & Maria De Santis. (2023) Treatable Traits in Systemic Sclerosis. Clinical Reviews in Allergy & Immunology 65:2, pages 251-276.
Crossref
Crossref
David Youssef, Susan Richards, Sabine Lague, Catherine Sheppard, Jenna Smith, Erika Vorhies, Martin Hosking, Matthew Pietrosanu & Angela Bates. (2023) A Canadian, retrospective, multicenter experience with selexipag for a heterogeneous group of pediatric pulmonary hypertension patients. Frontiers in Pediatrics 11.
Crossref
Crossref
Minshan Chen, Yuanqiang Lai, Riken Chen, Jianmin Lu, Yu Zhang, Haimin Liu, Donghao Wang, Yue Zhong, Zhenzhen Zheng & Cheng Hong. (2022) Efficacy and safety of selexipag, an oral prostacyclin receptor agonist for the treatment of pulmonary hypertension: A meta-analysis. Pulmonary Pharmacology & Therapeutics 72, pages 102100.
Crossref
Crossref
Yun Hwan Kim, Min Ki Jeong, Hyuntae Park & Sang Kab Park. (2021) Effects of Regular Taekwondo Intervention on Health-Related Physical Fitness, Cardiovascular Disease Risk Factors and Epicardial Adipose Tissue in Elderly Women with Hypertension. International Journal of Environmental Research and Public Health 18:6, pages 2935.
Crossref
Crossref
Miguel Dominguez‐Santas, Borja Diaz‐Guimaraens, Patricia Burgos‐Blasco, Daniel Ortega‐Quijano, Ana Suarez‐Valle & David Saceda‐Corralo. (2020) Rosacea induced by selexipag in a patient with pulmonary arterial hypertension. Dermatologic Therapy 33:6.
Crossref
Crossref
Monika Spaczyńska, Susana F. Rocha & Eduardo Oliver. (2020) Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies. ACS Pharmacology & Translational Science 3:4, pages 598-612.
Crossref
Crossref
Iwona Lewandowska Lewandowska, Monika Zielińska-Pisklak, Łukasz Szeleszczuk, Dariusz Maciej Pisklak & Marcin Sobczak. (2020) NADCIŚNIENIE PŁUCNE — PATOFIZJOLOGIA I LEKI WYKORZYSTYWANE W TERAPII. Prospects in Pharmaceutical Sciences 18:2, pages 10-18.
Crossref
Crossref
Martin Koestenberger & Georg Hansmann. (2018) Should we use the oral selective IP receptor agonist selexipag off‐label in children with pulmonary arterial hypertension?. Pulmonary Circulation 8:3, pages 1-4.
Crossref
Crossref
Eun-Hee Kim, Garam Hong, Seul-Hee Lee, Hyun-Hoon Jung & Sang-Kab Park. (2018) Effect of Longevity Exercise Program on Nitric Oxide and Endothelin-1 Concentration in the Elderly with Hypertension. The Korean Journal of Physical Education 57:3, pages 335-344.
Crossref
Crossref
Shirin Bruderer, Marc Petersen‐Sylla, Margaux Boehler, Tatiana Remeňová, Atef Halabi & Jasper Dingemanse. (2017) Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects. British Journal of Clinical Pharmacology 83:12, pages 2778-2788.
Crossref
Crossref
Uwe Fricke, Lutz Hein & Ulrich Schwabe. 2017. Arzneiverordnungs-Report 2017. Arzneiverordnungs-Report 2017
55
135
.